Crescent Biopharma, Inc. Common Stock (CBIO) is a publicly traded Healthcare sector company. As of November 12, 2026, CBIO trades at $15.13 with a market cap of $548.10M and a P/E ratio of -70.77. CBIO moved -2.20% today. Year to date, CBIO is +29.61%; over the trailing twelve months it is +10.34%. Its 52-week range spans $8.72 to $27.41. Analyst consensus is strong buy with an average price target of $30.80. Rallies surfaces CBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks CBIO insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $15.13 |
| Market Cap | $548.10M |
| P/E Ratio | -70.77 |
| EPS | $-0.20 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.41 |
| 52-Week Low | $8.72 |
| Volume | 176.97K |
| Avg Volume | 0 |
| Revenue (TTM) | $119.38M |
| Net Income | $-20.90M |
| Gross Margin | 94.30% |
5 analysts cover CBIO: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.80.